• First Rounders

    May 2018

    play full podcast


    • First rounders: John Maraganore

      John Maraganore is CEO of Alnylam Pharmaceuticals. In his talk with Nature Biotechnology he discusses his decade at Biogen, running an RNAi company when skepticism covered the field, and growing up the son of Greek immigrants in Chicago.

About the First Rounders Podcast

Nature Biotechnology's First Rounders podcast is a series of conversations with founders, financers and developers from biotech's past, present and future.


To subscribe for free to Nature Biotechnology's First Rounders podcast, copy and paste this URL into iTunes or your preferred media player: Nature Biotechnology Podcast rss feed.

If you would like to use part of any Nature Biotechnology podcast, please contact us at podcast@nature.com.

We welcome feedback so write to us at bioentrepreneur@us.nature.com. If you have any technical problems see the Help and FAQ section. All podcasts are © Nature Publishing Group.

Extra navigation

  • Sponsored by:

  • Archive

    • February 2018: First Rounders

      Jeff Leiden is chairman, president and CEO of Vertex Pharmaceuticals. His conversation with Nature Biotechnology covers rebuilding Vertex toward cystic fibrosis, competing for talent in the innovation economy and dropping out of high school to enter college early.


    • December 2017: First Rounders

      Susan is president and CEO of Biomedical Growth Strategies and was the founding president and CEO of the Massachusetts Life Sciences Center (MLSC). Her conversation with Nature Biotechnology covers her childhood in segregated St. Louis, her work at MLSC helping grow the life sciences sector in Massachusetts through Governor Deval Patrick's $1-billion initiative, and race relations in Boston and the United States.


    • October 2017: First Rounders

      Stelios Papadopoulos has been a biotech analyst, investment banker, and company founder. He's the current chairman of the board at Biogen. His conversation with Nature Biotechnology touches on his reasons for leaving Greece to come to the United States, how he made his mark in the nascent biotech analyst field, and his participation in late '60s radicalism.


    • August 2017: First Rounders

      Greg Winter is the Master of Trinity College, Cambridge, and a serial entrepreneur, who co-founded Cambridge Antibody Technology. Much of his career was spent at the Medical Research Council, and his research led to humanized monoclonal antibodies. His conversation with Nature Biotechnology covers growing up in west Africa, how suffering an attack in the street led to a breakthrough in the lab, and the state of UK biotech.


    • See complete archive